Sector News

Valeant weighs sales of controversial heart meds, laggard Provenge: Bloomberg

May 19, 2016
Life sciences

Valeant has been looking for ways to scale down its mountain of debt, and it may have landed on a couple.

The Canadian drugmaker is considering selling off Obagi Medical Products–a skincare buy from 2013–as well as Provenge, the laggard cancer vaccine it snapped up last year from bankrupt biotech Dendreon, according to Bloomberg’s sources. It’s also weighing a divestment of Isuprel and Nitropress, the jacked-up heart meds that last summer landed it in a wave of political and payer pushback that has yet to subside.

Of course, the sales process is still in the early stages–which could mean deals will happen for just some of those drugs, or none at all. But if Valeant can strike transactions for all of them, the divestitures could drum up a sum to the tune of $1 billion, the sources said.

It’s not the first time sales discussions have come up at the embattled drugmaker, which has been grappling with channel-stuffing allegations, underperforming sales and debt-default worries in addition to the pricing pressure. The company first broached the possibility of a sale of its controversial heart drugs last October, when then-CEO J. Michael Pearson admitted that holding onto the unit they belong to–Valeant’s neurology and “other” drugs business–“probably doesn’t make sense.”

And since then, new faces have cropped up at the Quebec-based pharma–and they’re eager to enact changes themselves. In March, shortly after joining Valeant’s board, activist investor Bill Ackman suggested selling part of eyecare business Bausch & Lomb could raise cash to pay down debt; the company could launch an IPO for a minority stake in the range of 10% to 20%, he reasoned.

One thing is certain–if it’s non-core assets Valeant is looking to shed, there are plenty of them to go around. The company made a number of debt-fueled buys after striking out on hostile target Allergan, some of which–such as Provenge, its first cancer med, and brodalumab, its first biologic candidate–raised eyebrows among industry watchers.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach